Scilex Holding (SCLX) Short-term Investments (2021 - 2026)
Scilex Holding (SCLX) recorded quarterly Short-term Investments of $200000.0 in Q1 2026, down 96.77% quarter-over-quarter from $6.2 million in Q4 2025.
Scilex Holding (SCLX) Short-term Investments (2021 - 2026) Analysis & Trends
Scilex Holding's Short-term Investments history runs 4 years deep, the most recent figure standing at $200000.0 for Q1 2026.
- In Q1 2026, Short-term Investments changed N/A year-over-year to $200000.0; the TTM figure through Mar 2026 stood at $200000.0 (changed N/A YoY), while the FY2025 annual figure was $6.2 million, changed N/A from the prior year.
- Short-term Investments was $200000.0 for Q1 2026 at Scilex Holding, down from $6.2 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $141.7 million in Q2 2022 to a low of $34961.0 in Q3 2022.
- Historically, Short-term Investments has averaged $57.7 million across 3 years, with a median of $6.2 million in 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn |
| 10 | Scilex Holding | 48.31 Mn | -101.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 6.20 Mn |
| Sep 30, 2022 | 34,961.00 |
| Jun 30, 2022 | 141.69 Mn |
| Mar 31, 2022 | 140.45 Mn |
| Dec 31, 2021 | 139.41 Mn |